FInalising Remplir (CelGro Nerve) submission for FDA....still....ATI vs surgery still on track for full recruitment in 2021 and at least, we are still getting the joint J&J ATI vs Corticosteroid study results in 2021, but otherwise a pretty mediocre 4C as is clear for all to see.
Revenues unexciting. Have to wait for the guided calander 4Q Straite efforts to come through I suppose.
Still J&J ATI results remain the biggest catalyst on the horizon in 4Q 2021, but a waiting game as ever.
Ann: Appendix 4C - Quarterly, page-2
Add OCC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
66.5¢ |
Change
-0.020(2.92%) |
Mkt cap ! $159.0M | |||
| Open | High | Low | Value | Volume |
| 67.0¢ | 67.0¢ | 65.0¢ | $245.7K | 371.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 15000 | 65.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 66.5¢ | 12621 | 2 |
View Market Depth
| Last trade - 16.10pm 13/11/2024 (20 minute delay) ? |
| OCC (ASX) Chart |